Streetbeat News

ATHE

Alterity Therapeutics Limited

https://alteritytherapeutics.com

Industry

Biotechnology

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Open

1.09

Mkt cap

10M

Volume

1.6K

High

1.11

P/E Ratio

-0.57

52-wk high

5.41

Low

1.09

Div yield

N/A

52-wk low

1.01

In Monday's after-market session, several health care stocks experienced significant movements. Sharps Technology (NASDAQ:STSS) saw the highest gain with an 87% increase, while DIH Holding US (NASDAQ:DHAI) experienced the largest decline, dropping by 24.4%. Other notable gainers include MorphoSys (NASDAQ:MOR) and Kintara Therapeutics (NASDAQ:KTRA), while Innovative Eyewear (NASDAQ:LUCY) and Scinai Immunotherapeutics (NASDAQ:SCNI) were among the notable losers.

Portfolio Pulse from Benzinga Insights

May 27, 2024 | 8:31 pm

In Friday's after-market session, several healthcare stocks showed notable movements. Lantern Pharma's shares surged 14.3% following their Q1 earnings release. Other gainers included Vaccinex, Purple Biotech, Dominari Holdings, Alterity Therapeutics, and Vaxart with increases in their stock prices. Conversely, Dermata Therapeutics, Solid Biosciences, Akanda, Aethlon Medical, Assure Holdings, and Synaptogenix experienced declines in their share prices.

Portfolio Pulse from Benzinga Insights

May 10, 2024 | 8:31 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. Helius Medical Tech led the gainers with a 48.9% increase, while AEON Biopharma experienced the largest drop among the losers, declining by 44.4%. Notably, Ardelyx and Owens & Minor reported their Q1 earnings, contributing to their stock increases.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 12:06 pm

Alterity Therapeutics (NASDAQ:ATHE) announced new data on ATH434's potential to treat Friedreich's Ataxia, presented at the World Orphan Drug Congress USA 2024. The study highlighted ATH434's unique ability to target toxic iron in the disease, differentiating it from traditional iron chelators.

Portfolio Pulse from Charles Gross

April 29, 2024 | 12:42 am

Health care stocks showed significant movement in Wednesday's intraday session, with notable gainers including Catheter Precision, Prenetics Global, and Alterity Therapeutics, among others. On the downside, GlucoTrack, Evotec, and Vaxxinity led the losers, with Evotec and Addex Therapeutics specifically reacting to their Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 4:31 pm

In Tuesday's after-market session, several healthcare stocks showed notable movements. Gainers included 180 Life Sciences, ABVC BioPharma, Medpace Holdings, Adverum Biotechnologies, Black Diamond Therapeutic, and Verve Therapeutics, with increases ranging from 4.94% to 7.4%. On the losing side, Fresh2 Group, Kiora Pharmaceuticals, Alterity Therapeutics, Tiziana Life Sciences, Calidi Biotherapeutics, and Nuwellis saw declines between 7.06% and 12.9%. Medpace Holdings' stock rise followed their Q1 earnings release.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 8:31 pm

Alterity Therapeutics presented three posters at the American Academy of Neurology 2024 Annual Meeting, showcasing their work on Parkinson's Disease and Multiple System Atrophy. The presentations included initial biomarker data and baseline characteristics from their ATH434-201 Phase 2 clinical trial.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 11:26 am

In Monday's after-market session, several healthcare stocks showed significant movement. Dynatronics led the gainers with a 70.1% increase, while Poseida Therapeutics experienced the largest drop among the losers, declining by 15.2%. The movements reflect varying market capitalizations and investor reactions to company-specific news or broader market trends.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 8:31 pm

In Monday's intraday session, several healthcare stocks experienced significant movements. Longeveron, Mobile-health Network, Jaguar Health, Soligenix, ProKidney, and Organovo Holdings were among the gainers, with increases ranging from 24.58% to 44.4%. Conversely, Marinus Pharma, Alterity Therapeutics, BioSig Technologies, Rallybio, MSP Recovery, and China SXT Pharmaceuticals faced declines, with Marinus Pharma dropping by 79.8%. The movements reflect varying market capitalizations and investor reactions to company-specific news, including MSP Recovery's Q4 earnings report.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 4:31 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. Soligenix, Longeveron, Cartesian Therapeutics, Biomerica, Allarity Therapeutics, and Envoy Medical were among the gainers, with Soligenix leading by a 95.1% increase. On the downside, Marinus Pharma, TRACON Pharma, Neumora Therapeutics, PaxMedica, Alterity Therapeutics, and SINTX Techs faced declines, with Marinus Pharma dropping by 74.5%. Biomerica's rise was attributed to its Q3 earnings release.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 12:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.